Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

HY21 result: Volpara (ASX:VHT) reports more solid growth

Breast-imaging business Volpara Health Technologies Ltd (ASX: VHT) has released its FY21 half result with more solid growth.

HY21 report

Volpara revealed that its total revenue increased by 38% to NZ$9.5 million, with subscription revenue jumping 71% on the prior corresponding period to NZ$8.8 million.

In terms of its annual recurring revenue, which is if its existing subscriber base paid for a full year of subscriptions over the next 12 months, it increased to NZ$19.9 million (up 26.7% compared to last year’s number of NZ$15.7 million).

In terms of market share, Volpara said that approximately 27% of women had a group product applied on their images and data compared to around 25.8% at the end of the corresponding period, equating to an increase of 1.2 percentage points. Average revenue per user (ARPU) was US$1.16 million, which was up approximately 26%.

The Volpara gross profit jumped by 42.9% to NZ$8.68 million with the gross profit margin increasing to 92%, up from 89%.

Volpara reported a net loss after tax (before foreign currency effects) of NZ$8.9 million, which was 11% worse than the prior corresponding period.

The company said that continued investment has been made in research and development with the roll out of its Volpara Breast Health Platform, which is an end to end solution that’s fully integrated and delivered through a virtual appliance.

Volpara finished the half-year period to 30 September 2020 with NZ$64.3 million of cash.

Volpara’s outlook

The company says that its revenue is on track to match management’s expectations for the full year. It expects annual recurring revenue to keep rising, but coronavirus impacts are causing growth to slow particularly at hospital-based imaging centres.

Volpara expects ARPU to keep rising, but it may lose some clinics as it targets legacy MRS customers in support contracts (at very low ARPU) to upgrade to SaaS or risk not being supported. The SaaS contracts have much higher ARPU.

It also expects to see increasing revenue from its partnership with genetics company Ambry, which is starting to show significant ARPU potential, well above internal expectations.

With the ongoing strength of the business, and the increasing ARPU, gross profit margin and market share, I think Volpara looks like a very promising business that is worth being (at least) on your watchlist.

There are other ASX growth shares that have very attractive scalability in my opinion such as Pushpay Holdings Ltd (ASX: PPH).

Are you stuck wondering where to invest right now? Have you got cash 'sitting on the sidelines'? Are you looking for dividend income AND growth but don't know where to start? Rask's expert ASX analyst team has just released a full report, detailing where we'd invest $10,000 right now.

Not only are we offering these 11 investment ideas completely FREE, we've also released an in-depth podcast to go with the report!

So, whether you have $2,000 or $50,000, our brand new analyst report could help transform your watchlist. Right now, you can get the full analyst report emailed to you for FREE by CLICKING HERE NOW or simply entering your email below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Are you stuck wondering where to invest right now? Have you got cash 'sitting on the sidelines'? Are you looking for dividend income AND growth but don't know where to start? Rask's expert ASX analyst team has just released a full report, detailing where we'd invest $10,000 right now.

Not only are we offering these 11 investment ideas completely FREE, we've also released an in-depth podcast to go with the report!

So, whether you have $2,000 or $50,000, our brand new analyst report could help transform your watchlist. Right now, you can get the full analyst report emailed to you for FREE by CLICKING HERE NOW.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

LIVE ASX Chat - Join in!

Keep reading:

ASX

A $2.3 million retirement challenge

In the lead up to (and in) retirement, I think too many people make costly mistakes with their money. So, I asked two financial planners how they’d tackle this problem.

Read More

Rask Analyst’s $10,000 Hypothetical Portfolio 

Rask Australia’s expert analysts have just released 11 stock & ETF positions they’d buy right now as part of a $10,000 hypothetical portfolio. 

Completely free, this report comes with the exact ticker codes, how much the analysts would invest and a detailed over the company and why we like it. Plus a 60-min podcast! 

Simply enter your email address and we’ll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.